Bo Rode Hansen

President & Chief Executive Officer, Member of the Board of Directors since May 2020

Education: MSc, PhD, MBA

Background: Bo Rode Hansen brings more than 20 years of international biotech and pharma business experience. Before joining Scandion Oncology, he most recently served as President & CEO at Genevant Sciences Inc. Prior to Genevant Sciences, he served as Global Head of Roche RNA Therapeutics & General Manager of Roche Innovation Center Copenhagen. Before Roche, Bo served as Executive, VP & Head of Drug Discovery & Alliances at Santaris Pharma, until the company was acquired by Roche.

Other ongoing assignments: Advisor to Novo Seeds and Abzu, Board member in Aloop Therapeutics

Independence: Not independent in relation to the Company and executive management but independent in relation to larger shareholders.

Scandion Oncology shares and warrants
42,442 shares and 1,071,688 warrants